WHAT IS CLAIMED IS:

1. A method for preventing or delaying the onset of myopia comprising administering to a subject in an eye a composition comprising less than 0.025% atropine.

2. The method of claim 1, wherein the atropine is present in the form of atropine salt.

3 . The method of claim 2, wherein the atropine salt is atropine sulfate or atropine acetate.

4. The method of claim 1, wherein the composition comprises about 0.01% atropine.

5. The method of claim 1, wherein the composition comprises about 0.001% to 0.0249% atropine.

6. The method of claim 1, wherein the composition comprising about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01 %, 0.011%, 0.012%, 0.013%, 0.014%, 0.015%, 0.016%, 0.017%, 0.018%, 0.019%, 0.02%, 0.021%, 0.022%, 0.023%, 0.024%, 0.0245% or 0.0249% atropine.

7. The method of claim 1, wherein the composition is administered every other day, or at least once daily, or at least twice daily.

8. The method of claim 1, wherein each administration is performed by instilling at least one drop, at least two drops, or at least three drops to the eye, wherein each drop contains about 20-100 microliter liquid.

9. The method of all preceding claims, wherein the adminstration continues for the period of at least six months, one year, two years, three years, four years, five years, six years, seven years, ten years or longer.

10. The method of claim 1, wherein the composition further comprises at least one pharmaceutically acceptable excipient.

11. The method of claim 1, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of benzalkonium chloride and hydroxypropyl methylcellulose.

12. The method of claim 11, wherein the benzalkonium chloride is present in the composition at a concentration of about 0.01%.

13. The method of claim 11, wherein the hydroxypropyl methylcellulose is present in the composition at a concentration of about 1%.

14. The method of claim 1, wherein the composition contains no preservatives.

15. The method of claim 1, wherein the subject is at least 5 years old.

16. The method according to claim 1, wherein the Spherical Equivalent (SE) of the eye is within the range of from +1.00D to -0.49D before administration of the composition.

17 The method of claim 16, wherein the SE is measured by Autorefractor after administration of cylcoplegia.

18. The method of claim 1, wherein the subject has no astigmastism or has astigamtism of not more than 1.50D as measured by cycloplegic or non-cycloplegic autorefraction before administration of the composition.

19. The method of claim 1, wherein the pupil of the eye has no dilation or a dialition of no greater than 0 2 mm during the period of administration of the composition.

20 . The method of claim 1, wherein the eye has no loss of accommodation or a loss of accommodation of no greater than 9D.

21. The method of any preceding claims, wherein the subject has at least one myopic parent.

22. The method of claim 1, wherein the onset of myopia is delayed for greater than 6 months, 12 months, 18 months, two years, three years, five years, six years, eight years, or longer.

23. A method for reducing or preventing myopia progression comprising administering to a subject in an eye a composition comprising less than 0.025% atropine,

wherein the composition is administered no more frequently than once every two days, once every three days, or once every four days.

24. The method of claim 23, wherein each administration is performed by instilling at least one drop, at least two drops, or at least three drops to the eye, wherein each drop contains about 20-100 microliter liquid.

25. The method of claim 23, wherein the SE of the eye is less than -1.50D before adminstration of the composition.

26 The method of claim 25, wherein the SE of the eye is within the range of from -0.50D to -1.50D before administration of the composition.

27. The method of claim 23, wherein the subject is at least 5 years old.

28. The method of claim 23, wherein the subject is between 5 and 9 years old.

29. The method of claim 23, wherein the atropine is present in the form of atropine sulphate.

30. The method of claim 23, wherein the composition comprises about 0.001% to 0.0249% atropine.

31. The method of claim 23, wherein the composition comprising about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01 %, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about 0.018%, about 0.019%, about 0.02%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.0245% or about 0.0249% atropine.

32. The method of claim 23, wherein the composition further comprises at least one pharmaceutically acceptable excipient.

33. The method of claim 32, wherein the at least one pharmaceutically acceptable excipient is selected from benzalkonium chloride and hydroxypropyl methylcellulose.

34. The method of claim 33, wherein the benzalkonium chloride is present in the composition and is at a concentration of about 0.01%.

35. The method of claim 33, wherein the hydroxypropyl methylcellulose is present in the composition at a concentration of about 1%.

36 . The method of claim 23, wherein the mean change of SE during a two year period following the start of administration of the composition is reduced by at least 20% as compared to controls.

37. The method of claim 23, wherein the pupil of the eye has no dilation or a dilation of no greater than 02 mm during the period of administration of the composition.

38. The method of claim 23, wherein the eye has no loss of accomodation or a loss of accommodation of no greater than 9D.

39. A composition for use in a method of preventing or delaying the onset of myopia progresssion, wherein the composition comprises less than 0.025% atropine.

40. The composition for use according to claim 39, wherein the composition comprises about 0.01% atropine.

41. The composition for use according to claim 39, wherein the composition comprises 0.001% to 0.0249% atropine.

42. The composition for use in a method of reducing or preventing myopia progression in a subject that has a SE of less than -1.50D, wherein the composition comprises less than 0.025% atropin, wherein the composition is administered no more frequently than once every two days.

43. The composition for use according to claim 39 or 42, wherein the composition further comprises at least one pharmaceutically acceptable excipient.

44. The composition for use according to claim 39, wherein the composition contains no preservatives.

1